Talking Cancer: Conversation with Ultramarathoner, Triathlete, Mother, Wife, Business Owner and Overachiever, Isabella de la Houssaye
To say Isabella de la Houssaye is an overachiever, would be minimizing what she is—a triathlete, a climber, a marathoner, a long-distance runner, a mother, wife and business owner, she epitomizes a
Using Real-World Lab Data Insights to Improve Biomarker Testing in Lung Cancer
As a medical community, our understanding of the lung cancer universe has become increasingly sophisticated in recent years and as a result, significant advancements have been seen in targeted ther
First CDx Approval for HLA Typing
We have seen HLA typing become more prominent in oncology clinical studies. Especially in the realm of immuno-oncology therapeutics including CAR T-cells, bi-specifics, and cancer vaccines.
Talking Cancer Blog: A Conversation with Holly Smithson, Athena CEO & Diversity Champion
ISO 15189 accreditation of the Swiss and Singapore NeoGenomics sites
In 2020 NeoGenomics decided to launch an accreditation program for its international sites in Switzerland and Singapore.
Entering the Multi-omics and precision medicine era in cancer research
Cancer hallmarks typically incorporate complex phenotypic and molecular changes including uncontrolled and sustained proliferation, evading growth suppressors, resisting
The Story, The Patient, The Activist
We wanted to start 2022 by reinforcing NeoGenomics Laboratories, Inc.’s promise to work toward state-of-the-art diagnostic and oncology testing for patients.
Perspectives on a ssPMA CDx submission
The proprietary, high sensitivity Sanger sequencing assay (LOD <1%), developed by NeoGenomics, was used in certain BeiGene Phase 2 and Phase 3 clinical studies to determine the MYD88 status of p